To Top

Community

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Contribution
Acquisition

Johnson & Johnson Announces Agreement to Acquire Auris Health, Inc.

PR-M02-19-NI-036
FDA Statement

Statement from FDA Commissioner Scott Gottlieb, M.D. on New Programs to Promote the Adoption of Innovations in Drug Manufacturing

PR-M02-19-NI-034
Collaboration

Abilita Bio and Amgen Enter Into a Multi-Target Collaboration

PR-M02-19-NI-035
Expansion

Discovery Life Sciences Launches Major European Expansion

PR-M02-19-NI-033
Genetic Testing

Invitae Launches Non-Invasive Prenatal Screening (NIPS), Offering In-Depth Genetic Information in Early Pregnancy

PR-M02-19-NI-031
License Agreement

Applied Biology to Enter into a License Agreement with Hairmore for its Novel Treatment for Traction Alopecia

PR-M02-19-NI-030
Funding

Culture Biosciences Secures $5.5M to Pioneer Biomanufacturing-as-a-Service

PR-M02-19-NI-029
FDA Approval

U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen

PR-M02-19-NI-028
Vaccine

Soligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate

PR-M02-19-NI-023
IND Approval

Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study

PR-M02-19-NI-022
Investment

KenSci Raises $22 Million in Series B Funding to Fuel Growth

PR-M02-19-NI-021
Genome Editing

Sangamo Announces Interim Results Of Phase 1/2 CHAMPIONS Study Showing Preliminary Evidence Of In Vivo Genome Editing In Patients With MPS II Treated With SB-913

PR-M02-19-NI-020
Innovation

Phillips-Medisize Named Winner of 2019 Pharmapack Innovation Award: Best Innovation in Drug Delivery

PR-M02-19-NI-024
Collaboration

Antidote Therapeutics Announces Collaboration with National Cancer Institute to Develop ATI-1013, a Novel Nicotine-Binding Antibody

PR-M02-19-NI-019
FDA Approval

Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System

PR-M02-19-NI-017
Acquisition

Optimapharm Acquires Swiss Denothex and Becomes a Leading European Mid-size Clinical Research Organization

PR-M02-19-NI-016
FDA Approval

U.S. FDA Approves Botox Competitor

PAO-M02-19-NI-005
Investment

3M Board Increases Dividend 6 Percent

PR-M02-19-NI-015
Clinical Trials

Arch Oncology Announces First Patient Dosed in Phase 1 Clinical Trial of AO-176, an Anti-CD47 Antibody with a Best-in-Class Profile

PR-M02-19-NI-012
Investment

Embleema Closes $3.7M Series A Funding Round and Joins Techstars Alchemist Blockchain Accelerator Program

PR-M02-19-NI-013
Collaboration

Torque and Thermo Fisher Scientific Announce Collaboration to Build State-of-the-Art Facility to Manufacture Torque's Deep-Primed T Cell Immunotherapies

PR-M02-19-NI-011
Phase III

Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study: Advances in Sleep and Circadian Science

PR-M02-19-NI-010
Appointment

INVO Bioscience Appoints Michael J. Campbell as COO & VP of Business Development

PR-M02-19-NI-009
Medical Device

Kaneka Invests in a US-based Medical Device Company

PR-M02-19-NI-008
Licensing

argenx Licenses Halozyme Subcutaneous Delivery Tech

PAO-M02-19-NI-002
Research

PTC Therapeutics Launches New Program to Support Research Projects in Rare, Genetic Disorders

PR-M02-19-NI-008
Appointment

Sanofi CEO Olivier Brandicourt Becomes PhRMA Board Chairman

PR-M02-19-NI-007
Acquistion

Altamont Capital Partners Acquires Publicis Healthcare Solutions

PR-M02-19-NI-006
FDA Approval

Mylan Announces FDA Approval of Wixela™ Inhub™, First Generic of ADVAIR DISKUS®

PR-M02-19-NI-005
Annoucement

Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction

PR-M02-19-NI-003
Clinical Trials

Clinical Trials Planned for Iris-Recognition-Based Patient Identification Software

PR-M02-19-NI-002
Alzheimer's Disease

Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer's Disease

PR-M02-19-NI-001
Press Releases

Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision

PR-M01-19-NI-096
Cancer Vaccines

Genetic Immunity Expands JSC Pharmadis Partnership by Granting 20 Cancer Vaccine Licenses for Russia and Commonwealth of Independent States

PR-M01-19-NI-093
Series B Funding

Phynd Technologies, Inc. Announces Completion of Series B Funding

PR-M01-19-NI-094
Milestone Payment

Perrigo To Receive Milestone Payment Of $250 Million From RPI Finance Trust

PR-M01-19-NI-095
Partnership

TrialScope and Vivli Partner to Address Rapidly Growing Transparency Needs of Clinical Trial Sponsors and Researchers

PR-M01-19-NI-090
Oncology

Trovagene and PoC Capital Enter Agreement to Fund Clinical Development of Onvansertib in Metastatic Colorectal Cancer (mCRC)

PR-M01-19-NI-089
Drug Pricing

Johnson & Johnson is Latest Pharma Company to Raise U.S. Prices

PAO-M01-19-NI-023
Artifical Intelligence

Anti-Aging Drug Development Company Applies Artificial Intelligence

PAO-M01-19-NI-017
FDA

BioInvent Receives FDA Orphan Designation for BI-1206 for Mantle Cell Lymphoma

PR-M01-19-NI-088
Partnership

Ampersand Health and MediQuire Announce Partnership to Move Providers to Value-Based Care

PR-M01-19-NI-087
Agreement

UPMC Health Plan Announces Innovative, Value-Based Agreement with AstraZeneca

PR-M01-19-NI-084
Drug Development

Bio-Techne Introduces CE-SDS PLUS for Maurice™ System

PR-M01-19-NI-083
Cell and Gene Therapy

Bio-Techne Launches Cell and Gene Therapy Portfolio

PR-M01-19-NI-080
Finance

Hovione Issues $50 Million Bond

PR-M01-19-NI-081
Environment

NYU Langone Launches Center to Study Environmental Exposures & Their Effects on Health

PR-M01-19-NI-077
Partnership

Novant Health Selects Genesis Automation for Enterprise Supply Chain

PR-M01-19-NI-075
Partnership

B-MoGen Biotechnologies and CytoSen Therapeutics Partner on Research Collaboration to Develop Next Generation Natural Killer Cells for Human Therapeutics

PR-M01-19-NI-072
Finance

BIOREM Announces Orders Totalling $3.6 Million

PR-M01-19-NI-071
Digital Health

RMDY Health Selected by MOBE to Deliver One-to-One Participant Engagement Across Digital Channels

PR-M01-19-NI-069
Oncology

Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®

PR-M01-19-NI-067
Oncology

ImaginAb Enrolls First Patient in Phase II Clinical Trial

PR-M01-19-NI-066
Offering

Biocept Announces Pricing of $2.2 Million Registered Direct Offering

PR-M01-19-NI-065
Leadership

Gaylord Specialty Healthcare Announces Sonja LaBarbera as President and CEO

PR-M01-19-NI-064
Opioids

New Study Shows Physician-Targeted Marketing is Associated with Increase in Opioid Overdose Deaths

PR-M01-19-NI-063
Veterinary

Bayer Introduces Versatile New Option for Heartworm Prevention and Intestinal Parasite Control

PR-M01-19-NI-062
Pancreatic Cancer

AbbVie Provides Update on Phase 3 Study of Ibrutinib (IMBRUVICA®) in Metastatic Pancreatic Cancer

PR-M01-19-NI-061
Pre-Natal

NX Prenatal and Milu Labs Announce Strategic Collaboration to Commercialize Exosome-Based Preterm Birth Risk Test in Asia

PR-M01-19-NI-059
Finance

First Light Diagnostics Closes $8.25 Million Series A-2 Financing

PR-M01-19-NI-058
Immunotherapy

AIVITA Biomedical Receives IND Clearance for Phase 1B Melanoma Trial

PR-M01-19-NI-056
Drug Development

Experimental Treatment Approach Shows Potential against Staphylococcus aureus

PR-M01-19-NI-055
Clinical Trials

Longeveron Recruiting For Stem Cell Alzheimer’s Trial In South Florida

PR-M01-19-NI-054
Analytic Model

New Analytic Model to Better Identify Patients Likely to Develop PTSD

PR-M01-19-NI-051
Launch

GenScript Launches Novel Technology Licensed from Amgen for Accelerating Protein and Antibody Purification

PR-M01-19-NI-050
Press Releases

ProKidney Announces $62 million Acquisition of inRegen

Appointment

Perrigo Appoints James Dillard To Role Of Chief Scientific Officer

PR-M01-19-NI-044
Hematology

Newly Discovered Phagocyte Plays Role in Autoimmune Disease

PR-M01-19-NI-044
Investment

CVS Health Announces $100 Million Community Commitment Following Acquisition Of Aetna

PR-M01-19-NI-044
Oncology Drugs

China Cancer Drugs Market 2018-2024: Rising Demand of Targeted Drug Therapy and the Patent Expiration of Key Cancer Drugs

PR-M01-19-NI-044
Lyophilization

Flow Sciences, Inc. Partners with Three Companies to Contain Lyophilization Process of New HPAPI

PR-M01-19-NI-052
Robotics

The Global Wearable Robotic Exoskeleton Market is Projected to Reach $5.4 Billion by 2028

PR-M01-19-NI-043
Expression System

Fujifilm Announces the Launch of Its Next Generation Apollo™ X Advanced Mammalian Expression System

PR-M01-19-NI-042
Myopia

SightGlass Vision Multicenter Trial to Study Novel Eyeglasses to Control Nearsightedness for FDA Approval

PR-M01-19-NI-040
Precision Diagnostics

Pillar Biosciences Enters Strategic Partnership with China Biotech Services Holdings to Deliver Precision Diagnostics to Markets in Asia

PR-M01-19-NI-041
Partnership

Abbott and "Malaria No More" Work Together to End Malaria in Odisha, India

PR-M01-19-NI-039
Investment

New Opioid-alternative Raises $3.25 Million for Phase I Trials

PR-M01-19-NI-037
Announcement

A Path Forward for Increasing Kidney Transplantation

PR-M01-19-NI-036
ALS Research

Collaborative Medicinal Development, LLC Reports that Lead Drug Modifies ALS Progression

PR-M01-19-NI-035
Hematology/Oncology

Blood Cancer Therapeutics: Global Markets to 2023

PR-M01-19-NI-034
Medical Device

Amgen Makes All Repatha® (evolocumab) Device Options Available In The US At A 60 Percent Reduced List Price

PR-M01-19-NI-033
RNA Splicing

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

PR-M01-19-NI-032
Immuno-oncology

Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs

PR-M01-19-NI-031
Leadership

AstraZeneca Announces Organizational Changes

PR-M01-19-NI-029
Approval

Novel Intrasaccular Aneurysm Treatment Device Receives FDA PMA Approval

PR-M01-19-NI-028
Immuno-oncology

Sanofi and Regeneron Immuno-oncology Collaboration Ending

PAO-M01-19-NI-012
R&D

Allergan Establishes R&D Group in Massachusetts

PAO-M01-19-NI-010
Facility

DPS Group Selected to Design Two cGMP Commercial Manufacturing Facilities for Brammer Bio

PR-M01-19-NI-036
Realignment

Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities

PR-M01-19-NI-024
Immuno-Oncology

PrimeVax Immuno-Oncology Receives IND Permission From FDA

PR-M01-19-NI-026
Investment

Vedanta Increases Investment

PAO-M01-19-NI-004
Drug Pricing

Drug Companies Raise Prices to Start New Year

PAO-M01-19-NI-003
Acquisition

Neogen Acquires Canadian Animal Genomics Laboratory

PR-M01-19-NI-011
Financial Results

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2019

PR-M01-19-NI-010
J.P. Morgan Healthcare Conference

Grace Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference

PR-M01-19-NI-009
Immuno-oncology

GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment

PR-M01-19-NI-023
FDA

PolarityTE Registers OsteoTE™ with U.S. Food and Drug Administration

PR-M01-19-NI-016
Drug Development

InventisBio and Betta Pharma to Co-Develop Novel Drug for Non-Small Cell Lung Cancer

PR-M01-19-NI-013
Acquisition

Rentschler Biopharma Completes Acquisition of U.S. Manufacturing Site

PR-M01-19-NI-021
Announcement

Baltimore Biotech Earns International Recognition for Advanced Development and Manufacturing Facility

PR-M01-19-NI-020
Appointment

Brammer Bolsters Leadership Team and Announces Chief Quality Officer

PR-M01-19-NI-019
M&A

Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company

PR-M01-19-NI-017